Experimental drug shows promise in advanced kidney cancer

Sep 26, 2007

Barcelona, Spain: A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.

The study, presented today (Wednesday) at the European Cancer Conference (ECCO 14) in Barcelona, showed that the experimental drug, axitinib, shrank tumours and delayed progression of the disease in a group of patients who are among the toughest to treat.

In the study, scientists gave axitinib to 62 patients whose kidney cancer had spread and who had not benefited from a standard treatment, sorafenib, a targeted therapy designed to disrupt cell division signals in cancer cells and block the tumour’s ability to form new blood vessels that help it grow. Fourteen of the patients also had been given – to no avail – another similarly targeted drug, sunitinib, after the sorafenib had failed to work. Axitinib works similarly to the other two but is believed to be more potent.

“More than half the patients – 51 percent – experienced tumour shrinkage and in 23 percent of them the shrinkage is considered significant,” said lead investigator Dr Brian I. Rini, an associate professor of medicine at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, USA, and a paid member of the Pfizer scientific advisory board. “Preliminary analysis shows the progression-free survival was on average more than 7.7 months. We think these results are impressive because these patients were heavily pre-treated and with drugs thought to be similar to axitinib.

“The disease progressed in only 24 percent of patients, which we think is low in this kind of setting,” Rini added. The study found the tumour remained stable in 37 percent of the patients.

“Historically, metastatic kidney cancer has been very tough to treat, with a median survival of 12 months. Through the results of this trial, it appears that axitinib is a very active drug in renal cell cancer that can benefit a large number of patients,” Rini added.

The drug’s maker, Pfizer, paid for the study. Axitinib is also being tested in advanced pancreatic, thyroid, lung and breast cancers.

Source: ECCO-the European CanCer Conference

Explore further: Researchers find chemotherapy after bladder cancer surgery improved survival

add to favorites email to friend print save as pdf

Related Stories

Canada looks east-west to ship oil after Keystone veto

3 hours ago

After US President Barack Obama vetoed a bill to expedite construction of the Keystone XL pipeline Tuesday, petroleum producers are expected to turn to Canadian routes to ship oil internationally, but hurdles ...

Internet access limited in developing world

3 hours ago

Most people in the developing world do not use the Internet, with access limited by high costs, poor availability and a lack of relevant content, a Facebook report said Tuesday.

Manhattan Project physicist Ralph Nobles dies at 94

3 hours ago

(AP)—Ralph Nobles, a nuclear physicist who worked on the Manhattan Project and later led efforts to save thousands of acres of San Francisco Bay wetlands from development, died following complications of pneumonia, according ...

In Japan, robot dogs are for life - and death

3 hours ago

Incense smoke wafts through the cold air of the centuries-old Buddhist temple as a priest chants a sutra, praying for the peaceful transition of the souls of the departed.

US sees little severe weather so far in 2015

3 hours ago

(AP)—While a big chunk of the nation deals with snow and ice, the U.S. is poised to end January and February with the fewest bouts of severe weather in decades.

Recommended for you

Deodorant use ok for radiotherapy patients

12 hours ago

Women undergoing radiotherapy for breast cancer can use deodorant without fear of increased underarm skin reaction, pain, itching or burning, research suggests.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.